Search Results - "Hosing C"

Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.

Authors: Hosing, C. Saliba, R. M. Shahjahan, M. et al.

Source: Bone Marrow Transplantation. Jul2005, Vol. 36 Issue 2, p157-162. 6p.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

Authors: Popat, U. Hosing, C. Saliba, R. M. et al.

Source: Bone Marrow Transplantation. May2004, Vol. 33 Issue 10, p1015-1023. 9p.

The choice of allogeneic or autologous hematopoietic transplantation for NHL.

Authors: Hosing, C Champlin, RE

Source: Cytotherapy (Taylor & Francis Ltd). May2002, Vol. 4 Issue 3, p259-269. 11p.

Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.

Authors: Hosing, C. Bassett, R. Dabaja, B. et al.

Source: Annals of Oncology. Dec2015, Vol. 26 Issue 12, p2490-2495. 6p. 2 Charts, 1 Graph.

Stem-cell transplantation in T-cell non-Hodgkin’s lymphomas.

Authors: Hosing, C. Champlin, R. E.

Source: Annals of Oncology. Jul2011, Vol. 22 Issue 7, p1471-1477. 7p. 3 Charts.

Umbilical cord blood graft engineering: challenges and opportunities.

Authors: Thompson, P A Rezvani, K Hosing, C M et al.

Source: Bone Marrow Transplantation. Jun2015 Supplement, Vol. 50, pS55-S62. 8p.

Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.

Authors: Qazilbash, M. H. Saliba, R. M. Hosing, C. et al.

Source: Bone Marrow Transplantation. Mar2007, Vol. 39 Issue 5, p279-283. 5p. 2 Charts, 1 Graph.

An Analysis of the Charges Associated With Peripheral Blood Hematopoietic Progenitor Cell (HPC) Mobilization, Collection and Cryopreservation In Patients With Lymphomas Undergoing Autologous Stem Cell Transplantation

Authors: Walters, K.H. Hosing, C. Smith, V.R. et al.

Source: Biology of Blood & Marrow Transplantation. Feb2009 Supplement, Vol. 15, p71-72. 2p.

Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory hodgkin lymphoma (HL)

Authors: Jabbour, E. Hosing, C. Pro, B. et al.

Source: Biology of Blood & Marrow Transplantation. Feb2006 Supplement 1, Vol. 12, p114-115. 2p.

New Mobilization Strategies for Collection of Peripheral Blood Progenitor Cells for Lymphoma and Myeloma Patients

Authors: Smith, V.R. Hosing, C. Popat, U. et al.

Source: Biology of Blood & Marrow Transplantation. Feb2009 Supplement, Vol. 15, p29-29. 1p.

Extracorporeal photochemotherapy for (ECP) the treatment of chronic graft-versus-host disease

Authors: Couriel, D.R. Hosing, C. Anderlini, P. et al.

Source: Biology of Blood & Marrow Transplantation. Feb2005 Supplement 1, Vol. 11, p48-48. 1p.

Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation.

Authors: Qazilbash, M. H. Ueno, N. T. Hosing, C. et al.

Source: Bone Marrow Transplantation. Sep2006, Vol. 38 Issue 5, p393-394. 2p. 1 Black and White Photograph.

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

Authors: Shah, N Thall, P F Fox, P S et al.

Source: Leukemia (08876924). Sep2015, Vol. 29 Issue 9, p1945-1948. 4p. 1 Chart, 1 Graph.

Is there an expiration date for a cord blood unit in storage?

Authors: Parmar, S de Lima, M Worth, L et al.

Source: Bone Marrow Transplantation. Aug2014, Vol. 49 Issue 8, p1109-1112. 4p.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.

Authors: Wang, M Fowler, N Wagner-Bartak, N et al.

Source: Leukemia (08876924). Sep2013, Vol. 27 Issue 9, p1902-1909. 8p. 1 Black and White Photograph, 3 Charts, 1 Graph.

Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.

Authors: Yilmaz, M Chemaly, R F Han, X Y et al.

Source: Bone Marrow Transplantation. Sep2013, Vol. 48 Issue 9, p1218-1223. 6p. 3 Charts, 2 Graphs.

Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

Authors: Poon, L M Bassett Jr, R Rondon, G et al.

Source: Bone Marrow Transplantation. May2013, Vol. 48 Issue 5, p666-670. 5p. 4 Charts.

Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.

Authors: Kebriaei, P Madden, T Wang, X et al.

Source: Bone Marrow Transplantation. Jan2013, Vol. 48 Issue 1, p26-31. 6p. 4 Charts, 4 Graphs.

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

Authors: Popat, U de Lima, M J Saliba, R M et al.

Source: Bone Marrow Transplantation. Feb2012, Vol. 47 Issue 2, p212-216. 5p. 2 Charts, 3 Graphs.

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.

Authors: Kazmi, S. M. A. Saliba, R. M. Donato, M. et al.

Source: Bone Marrow Transplantation. Apr2011, Vol. 46 Issue 4, p510-515. 6p. 4 Charts, 1 Graph.